DOP2000000069A - Inhibidores triciclicos de polimerasas (adp-polirribosas - Google Patents

Inhibidores triciclicos de polimerasas (adp-polirribosas

Info

Publication number
DOP2000000069A
DOP2000000069A DO2000000069A DO2000000069A DOP2000000069A DO P2000000069 A DOP2000000069 A DO P2000000069A DO 2000000069 A DO2000000069 A DO 2000000069A DO 2000000069 A DO2000000069 A DO 2000000069A DO P2000000069 A DOP2000000069 A DO P2000000069A
Authority
DO
Dominican Republic
Prior art keywords
adp
trimycly
polyriboses
polymerase inhibitors
compounds
Prior art date
Application number
DO2000000069A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Evan Webber
Donald James Skalitzky
Jayashree Girish Tikhe
Robert Arnold Kumpf
Joseph Timothy Marakovits
Brian Walter Eastman
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of DOP2000000069A publication Critical patent/DOP2000000069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DO2000000069A 1999-08-31 2000-09-20 Inhibidores triciclicos de polimerasas (adp-polirribosas DOP2000000069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
DOP2000000069A true DOP2000000069A (es) 2002-08-30

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2000000069A DOP2000000069A (es) 1999-08-31 2000-09-20 Inhibidores triciclicos de polimerasas (adp-polirribosas

Country Status (48)

Country Link
US (1) US6548494B1 (enExample)
EP (1) EP1208104B1 (enExample)
JP (1) JP4272375B2 (enExample)
KR (1) KR20020038742A (enExample)
CN (1) CN1384835A (enExample)
AP (1) AP1553A (enExample)
AR (1) AR035162A1 (enExample)
AT (1) ATE287406T1 (enExample)
AU (1) AU781826B2 (enExample)
BG (1) BG106562A (enExample)
BR (1) BR0015051A (enExample)
CA (1) CA2382404C (enExample)
CO (1) CO5200769A1 (enExample)
CR (1) CR6577A (enExample)
CZ (1) CZ2002613A3 (enExample)
DE (1) DE60017575T2 (enExample)
DK (1) DK1208104T3 (enExample)
DO (1) DOP2000000069A (enExample)
DZ (1) DZ3216A1 (enExample)
EA (1) EA200200306A1 (enExample)
EC (1) ECSP003637A (enExample)
EE (1) EE200200100A (enExample)
ES (1) ES2234657T3 (enExample)
GE (1) GEP20043268B (enExample)
GT (1) GT200000145A (enExample)
HK (1) HK1045509B (enExample)
HR (1) HRP20020271A2 (enExample)
HU (1) HUP0202703A3 (enExample)
IL (1) IL147863A0 (enExample)
IS (1) IS6289A (enExample)
MA (1) MA25876A1 (enExample)
MX (1) MXPA02002138A (enExample)
MY (1) MY135910A (enExample)
NO (1) NO322475B1 (enExample)
NZ (1) NZ516793A (enExample)
OA (1) OA12016A (enExample)
PA (1) PA8501801A1 (enExample)
PE (1) PE20010538A1 (enExample)
PL (1) PL354242A1 (enExample)
PT (1) PT1208104E (enExample)
SI (1) SI1208104T1 (enExample)
SK (1) SK2592002A3 (enExample)
SV (1) SV2003000162A (enExample)
UA (1) UA73144C2 (enExample)
UY (1) UY26323A1 (enExample)
WO (1) WO2001016136A2 (enExample)
YU (1) YU15102A (enExample)
ZA (1) ZA200200830B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
CN1374961A (zh) * 1999-09-28 2002-10-16 巴斯福股份公司 氮杂䓬吲哚衍生物,它们的制备和应用
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
HRP20050624A2 (en) 2003-01-09 2006-02-28 Pfizer Inc. Diazepinoindole derivatives as kinaze inhibitors
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
ATE521341T1 (de) 2003-12-01 2011-09-15 Kudos Pharm Ltd Dna-schäden-reparatur-hemmer zur behandlung von krebs
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
WO2006033003A1 (en) * 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
MX2007008771A (es) * 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
AR053902A1 (es) 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
WO2006137510A1 (ja) 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
CN101268077A (zh) * 2005-08-05 2008-09-17 阿斯利康(瑞典)有限公司 三环苯并咪唑及其作为代谢型谷氨酸受体调节剂的用途
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
JP2011506343A (ja) * 2007-12-07 2011-03-03 バイパー サイエンシズ，インコーポレイティド トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
JP2011521618A (ja) * 2008-02-04 2011-07-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ仲介疾患を診断および治療する方法
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
LT2346495T (lt) 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
BR112015004311A2 (pt) * 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de benzodiazepinonas e benzazepinonas substituídas ou os sais das mesmas como substâncias ativas contra estresse abiótico de planta
EP3424909A1 (en) * 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
MA51524A (fr) 2018-01-05 2020-11-11 Cybrexa 1 Inc Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
AU2019235337A1 (en) 2018-03-13 2020-08-27 Centre National De La Recherche Scientifique A Dbait molecule against acquired resistance in the treatment of cancer
TW202019408A (zh) * 2018-06-28 2020-06-01 美商永恒生物科技公司 稠合三環雜環化合物及其治療用途
CN111386275B (zh) * 2018-08-24 2023-03-10 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
KR20210125024A (ko) * 2019-02-02 2021-10-15 치아타이 티안큉 파마수티컬 그룹 주식회사 Parp 억제제로서의 인돌로 헵타밀 옥심 유사체
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
PE20220485A1 (es) 2019-07-10 2022-04-04 Cybrexa 3 Inc Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
US20240093250A1 (en) 2021-01-08 2024-03-21 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
AU2024312126A1 (en) 2023-06-21 2025-12-11 Tetragon Biosciences Ltd. Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (enExample) 1964-03-24
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CA2150345A1 (en) 1993-09-28 1995-04-06 Makoto Komatsu Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
IL123147A (en) * 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
WO1998051307A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity

Also Published As

Publication number Publication date
WO2001016136A3 (en) 2001-06-21
BG106562A (bg) 2003-03-31
CR6577A (es) 2003-12-05
YU15102A (sh) 2004-12-31
PT1208104E (pt) 2005-04-29
ZA200200830B (en) 2003-03-26
DE60017575T2 (de) 2005-06-09
DZ3216A1 (fr) 2001-03-08
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
CN1384835A (zh) 2002-12-11
SI1208104T1 (en) 2005-06-30
MY135910A (en) 2008-07-31
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
AU781826B2 (en) 2005-06-16
HK1045509A1 (en) 2002-11-29
HRP20020271A2 (en) 2005-12-31
HUP0202703A2 (hu) 2002-12-28
PE20010538A1 (es) 2001-05-22
ECSP003637A (es) 2002-03-25
AU7338900A (en) 2001-03-26
CA2382404C (en) 2009-03-24
GT200000145A (es) 2002-02-21
GEP20043268B (en) 2004-06-25
EP1208104B1 (en) 2005-01-19
MXPA02002138A (es) 2003-08-20
NO322475B1 (no) 2006-10-09
IL147863A0 (en) 2002-08-14
JP2003513015A (ja) 2003-04-08
KR20020038742A (ko) 2002-05-23
DE60017575D1 (de) 2005-02-24
UA73144C2 (en) 2005-06-15
MA25876A1 (fr) 2003-10-01
PA8501801A1 (es) 2002-08-26
WO2001016136B1 (en) 2001-11-15
HUP0202703A3 (en) 2004-12-28
EP1208104A2 (en) 2002-05-29
PL354242A1 (en) 2003-12-29
BR0015051A (pt) 2002-06-25
UY26323A1 (es) 2001-04-30
NO20020421L (no) 2002-04-25
AP1553A (en) 2006-01-18
NZ516793A (en) 2004-03-26
CA2382404A1 (en) 2001-03-08
ES2234657T3 (es) 2005-07-01
IS6289A (is) 2002-02-27
EE200200100A (et) 2003-06-16
AR035162A1 (es) 2004-05-05
EA200200306A1 (ru) 2002-08-29
ATE287406T1 (de) 2005-02-15
NO20020421D0 (no) 2002-01-28
JP4272375B2 (ja) 2009-06-03
DK1208104T3 (da) 2005-05-02
CO5200769A1 (es) 2002-09-27
CZ2002613A3 (cs) 2002-08-14
HK1045509B (en) 2005-04-29
SK2592002A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
DOP2000000069A (es) Inhibidores triciclicos de polimerasas (adp-polirribosas
EA200100764A1 (ru) Трициклические ингибиторы поли(adp-рибозо) полимераз
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TR200200717T2 (tr) Terapötik kinazolin türevleri.
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
UY28833A1 (es) Piridonas sustituidas como inhibidores de poli (adp-ribosa)-polimerasa (parp).
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
MY138352A (en) Benzothiazole derivatives
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
MXPA03006863A (es) Derivados de oxazolilpirazol com inhibidores de cinasa.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
UY28245A1 (es) Sales de los inhibidores tricíclicos de las poli(adp-ribosa) polimerasas
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
PT1212312E (pt) Novos derivados de flavonas xantonas e cumarinas
AR028705A1 (es) Bis-arilsulfonas
EP1643984A4 (en) USE OF PARTHENOLID DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
ATE238981T1 (de) Antitumorwirkstoffe
TR200003122T2 (tr) Aril bağlı azapolisiklik bileşikler
ATE389655T1 (de) Pyrimidinderivate
ATE368649T1 (de) Cyanoguanidin prodrugs